301 related articles for article (PubMed ID: 33257427)
1. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
Keenan TE; Li T; Vallius T; Guerriero JL; Tayob N; Kochupurakkal B; Davis J; Pastorello R; Tahara RK; Anderson L; Conway J; He MX; Shannon E; Godin RE; Sorger PK; D'Andrea A; Overmoyer B; Winer EP; Mittendorf EA; Van Allen EM; Shapiro GI; Tolaney SM
Clin Cancer Res; 2021 Feb; 27(4):983-991. PubMed ID: 33257427
[TBL] [Abstract][Full Text] [Related]
2. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K
Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
Liu JF; Xiong N; Campos SM; Wright AA; Krasner C; Schumer S; Horowitz N; Veneris J; Tayob N; Morrissey S; West G; Quinn R; Matulonis UA; Konstantinopoulos PA
J Clin Oncol; 2021 May; 39(14):1531-1539. PubMed ID: 33705205
[TBL] [Abstract][Full Text] [Related]
4. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of WEE1 Is Effective in
Seligmann JF; Fisher DJ; Brown LC; Adams RA; Graham J; Quirke P; Richman SD; Butler R; Domingo E; Blake A; Yates E; Braun M; Collinson F; Jones R; Brown E; de Winton E; Humphrey TC; Parmar M; Kaplan R; Wilson RH; Seymour M; Maughan TS;
J Clin Oncol; 2021 Nov; 39(33):3705-3715. PubMed ID: 34538072
[TBL] [Abstract][Full Text] [Related]
6. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP
Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809
[TBL] [Abstract][Full Text] [Related]
7. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N;
Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040
[TBL] [Abstract][Full Text] [Related]
8. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
Cuneo KC; Morgan MA; Sahai V; Schipper MJ; Parsels LA; Parsels JD; Devasia T; Al-Hawaray M; Cho CS; Nathan H; Maybaum J; Zalupski MM; Lawrence TS
J Clin Oncol; 2019 Oct; 37(29):2643-2650. PubMed ID: 31398082
[TBL] [Abstract][Full Text] [Related]
9. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the
Kong A; Good J; Kirkham A; Savage J; Mant R; Llewellyn L; Parish J; Spruce R; Forster M; Schipani S; Harrington K; Sacco J; Murray P; Middleton G; Yap C; Mehanna H
BMJ Open; 2020 Mar; 10(3):e033009. PubMed ID: 32184305
[TBL] [Abstract][Full Text] [Related]
11. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
Chera BS; Sheth SH; Patel SA; Goldin D; Douglas KE; Green RL; Shen CJ; Gupta GP; Moore DT; Grilley Olson JE; Weiss JM
Cancer; 2021 Dec; 127(23):4447-4454. PubMed ID: 34379792
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial.
Gatz SA; Harttrampf AC; Brard C; Bautista F; André N; Abbou S; Rubino J; Rondof W; Deloger M; Rübsam M; Marshall LV; Hübschmann D; Nebchi S; Aerts I; Thebaud E; De Carli E; Defachelles AS; Paoletti X; Godin R; Miah K; Mortimer PGS; Vassal G; Geoerger B
Clin Cancer Res; 2024 Feb; 30(4):741-753. PubMed ID: 38051741
[TBL] [Abstract][Full Text] [Related]
15. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract][Full Text] [Related]
16. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
[TBL] [Abstract][Full Text] [Related]
19. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.
Chen J; Jia X; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
Biochem Pharmacol; 2021 Jun; 188():114494. PubMed ID: 33684390
[TBL] [Abstract][Full Text] [Related]
20. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
